Novo Nordisk raised its 2026 adjusted sales and operating-profit outlook to a range of +2% to -2% at constant exchange rates, after Wegovy pill sales reached 5.39 billion Danish crowns in the third quarter, above the 4.62 billion consensus.
Novo Nordisk’s Wegovy weight-loss pill generated 5.39 billion Danish crowns ($810 million) in third-quarter sales, up 53% from the second quarter and above the 4.62 billion consensus. The U.S. accounted for 4.18 billion crowns and international markets for 1.22 billion; U.S. prescriptions were about 3.6 million during the quarter and more than 8 million since launch.
The company raised its 2026 adjusted sales and adjusted operating-profit forecast to a range of +2% to -2% at constant exchange rates, from a previous forecast of a 0% to 6% decline. It said higher expectations for GLP-1 sales in the U.S. and international markets drove the improvement, marking its third guidance increase this year. Adjusted operating profit was 31.72 billion Danish crowns and adjusted sales were 79.20 billion, both above analyst estimates. U.S. sales of injectable Wegovy fell 13% at constant exchange rates, while combined U.S. Wegovy sales rose 21%.
